29 October 2015: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces the appointment of Professor Trevor Mervyn Jones CBE, aged 73, to the Board of Directors as a Non-Executive Director. Professor Jones has today joined the Company. Dr Rajesh Chopra, Non-Executive Director, has also resigned to return to a full-time academic research career.
Professor Jones has over 40 years’ distinguished experience in the pharmaceutical and biotech industry as well as in academia. He is currently Chairman of the international CRO, Simbec-Orion Group Limited and Welsh investment company, Arthurian Life Sciences Limited. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities.
Previously, he has held significant roles in industry including Director of Allergan Inc from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987-1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines.
He has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry (ABPI) from 1994 to 2004, board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). For 12 years, Professor Jones was a member of the UK Government regulatory agency, The Medicines Commission. He was a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals and adviser to the Cabinet Office on the Human Genome Project in2001. He has also been a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research.
Professor Jones is a founder member of the Hever Group, a forum of the heads of research and development of large pharmaceutical companies that was formed to discuss issues facing the industry and solutions for addressing common challenges.
Commenting on the appointment, Professor Malcolm Young, CEO of e-Therapeutics, said: “Professor Jones’ exceptional research and development experience and illustrious record will be an immensely valuable addition to the team as we ramp up towards realising the commercial potential of our discovery and development assets. I would also like to thank Raj Chopra on behalf of e-Therapeutics for his long and considerable contributions to the Company and we all wish him well in the next stage of his career.
“The appointment of Professor Jones further supports our new primary focus on commercialising our most promising compounds and programmes.”
Current directorships:
Arthurian Life Sciences Limited
Simbec-Orion Group Limited
The UK Stem Cell Foundation
Directorships held in the last five years:
Allergan Inc
Nextpharma Technologies Holding Limited
Reneuron (UK) Limited
Reneuron Group plc
Reneuron Holdings Limited
Reneuron Limited
Sciclone Pharmaceuticals Inc
Sigma Tau Finanziaria SpA
Sigma-Tau Industrie Farmaceutiche Riunite SpA
Sigma-Tau Pharmaceuticals Inc
Sigma Topco Limited
Simbec Research Limited
Synexus Clinical Research Topco Limited
Synexus Clinical Research Midco No 2 Limited
Synexus Clinical Research Midco No 4 Limited
Tecnogen SpA
The British Neurological Research Trust
Verona Pharma plc
Trevor Jones holds no ordinary shares in the Company. In relation to the appointment of Professor Jones to the Board of Directors, e-Therapeutics confirms that there is nothing further to disclose in relation to his appointment under AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies except as disclosed in this announcement.
Help employers find you! Check out all the jobs and post your resume.
